| 1A8J | H:112-216; L:112-216 | IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME |
| 1ADQ | L:108-215 | CRYSTAL STRUCTURE OF A HUMAN IGM RHEUMATOID FACTOR FAB IN COMPLEX WITH ITS AUTOANTIGEN IGG FC |
| 1AQK | L:112-216 | THREE-DIMENSIONAL STRUCTURE OF A HUMAN FAB WITH HIGH AFFINITY FOR TETANUS TOXOID |
| 1BJM | A:112-216; B:112-216 | LOC NAKS, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN NAKSO4 |
| 1DCL | A:112-216; B:112-216 | MCG, A LAMBDA V TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN), CRYSTALLIZED FROM AMMONIUM SULFATE |
| 1JVK | A:113-216; B:113-215 | THREE-DIMENSIONAL STRUCTURE OF AN IMMUNOGLOBULIN LIGHT CHAIN DIMER ACTING AS A LETHAL AMYLOID PRECURSOR |
| 1LGV | A:113-214; B:113-214 | STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 100K |
| 1LHZ | A:113-214; B:113-214 | STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 293K |
| 1LIL | A:108-215; B:108-215 | BENCE JONES PROTEIN CLE, A LAMBDA III IMMUNOGLOBULIN LIGHT-CHAIN DIMER |
| 1MCB | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCC | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCD | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCE | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCF | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCH | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCI | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCJ | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCK | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCL | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCN | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCO | L:112-216 | THREE-DIMENSIONAL STRUCTURE OF A HUMAN IMMUNOGLOBULIN WITH A HINGE DELETION |
| 1MCQ | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCR | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCS | A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
| 1MCW | M:112-216; W:112-216 | THREE-DIMENSIONAL STRUCTURE OF A HYBRID LIGHT CHAIN DIMER. PROTEIN ENGINEERING OF A BINDING CAVITY |
| 1NC2 | A:111-211; C:111-215 | CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY 2D12.5 FAB COMPLEXED WITH Y-DOTA |
| 1NC4 | A:111-211; C:111-215 | CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY 2D12.5 FAB COMPLEXED WITH GD-DOTA |
| 1NJ9 | A:109-210; L:109-210 | COCAINE HYDROLYTIC ANTIBODY 15A10 |
| 1NL0 | L:109-210 | CRYSTAL STRUCTURE OF HUMAN FACTOR IX GLA DOMAIN IN COMPLEX OF AN INHIBITORY ANTIBODY, 10C12 |
| 1PG7 | W:109-206; Y:109-206 | MURINE 6A6 FAB IN COMPLEX WITH HUMANIZED ANTI-TISSUE FACTOR D3H44 FAB |
| 1Q0X | L:108-212 | ANTI-MORPHINE ANTIBODY 9B1 UNLIGANDED FORM |
| 1Q0Y | L:108-212 | ANTI-MORPHINE ANTIBODY 9B1 COMPLEXED WITH MORPHINE |
| 1Q1J | L:109-213; M:109-213 | CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 PEPTIDE |
| 1RZF | L:109-210 | CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY E51 |
| 1ZVO | A:110-214; B:110-214 | SEMI-EXTENDED SOLUTION STRUCTURE OF HUMAN MYELOMA IMMUNOGLOBULIN D DETERMINED BY CONSTRAINED X-RAY SCATTERING |
| 2DD8 | L:109-213 | CRYSTAL STRUCTURE OF SARS-COV SPIKE RECEPTOR-BINDING DOMAIN COMPLEXED WITH NEUTRALIZING ANTIBODY |
| 2FB4 | L:110-214 | DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN) |
| 2G75 | B:109-211; D:109-211 | CRYSTAL STRUCTURE OF ANTI-SARS M396 ANTIBODY |
| 2IG2 | L:110-214 | DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN) |
| 2J6E | L:109-210 | CRYSTAL STRUCTURE OF AN AUTOIMMUNE COMPLEX BETWEEN A HUMAN IGM RHEUMATOID FACTOR AND IGG1 FC REVEALS A NOVEL FC EPITOPE AND EVIDENCE FOR AFFINITY MATURATION |
| 2MCG | 1:112-216; 2:112-216 | THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS |
| 3BJL | A:112-216; B:112-216 | LOC, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN AMMONIUM SULFATE |
| 3MCG | 1:112-216; 2:112-216 | THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS |
| 4BJL | A:112-216; B:112-216 | LOCW, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN DISTILLED WATER |
| 7FAB | L:104-204 | CRYSTAL STRUCTURE OF HUMAN IMMUNOGLOBULIN FRAGMENT FAB NEW REFINED AT 2.0 ANGSTROMS RESOLUTION |
| 8FAB | A:106-208; C:106-208 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT FROM THE HUMAN MYELOMA IMMUNOGLOBULIN IGG HIL AT 1.8 ANGSTROMS RESOLUTION |
)
)